Max-Drol

Max-Drol

77.00

Manufacturer: Maxtreme
Substance: Oxymetholone
Package: 10 mg / tab. (100 tab.)

Description

General information on Oxydrol Tablets in Italy

The only oral anabolic androgenic indicated in the treatment of anemia caused by the production of deficient red blood cells. Androlic is contraindicated in: male patients with prostate or breast cancer; females with hypercalcemia with breast cancer; women who are or may become pregnant; patients with nephrosis or the nephrotic stage of nephritis; patients with hypersensitivity to the drug or with severe liver dysfunction. Oxydrol 50mg (Oxymetholone) British Dragon Presentation The tablets are green square tablets, with 50 embossed on one side and BD separated by a score line, can be split into 2 parts, and are sealed in 100 foil pouches. tablets.

Features Oxydrol Tablets in Italy

Oxydrol BD is an oral drug at a dose of 50 mg per tablet. It is strongest oral on the market. It has both high androgenic and anabolic effects. Strength and weight gains are very significant. It is highly toxic to the liver. Oxydrol BD also aromatizes quite easily. Oxymetholone has been reported to produce gynecomastia users (not all probably around 50%). An anti-estrogen should be used to counter aromatization. Nolvadex is a suggested anti-estrogen. Many side effects are associated including acne, hair loss, abdominal pain, headache, gynecomastia, hypertension and heavy water retention. Weight loss and strength usually occurs after your period.

Buy Oxydrol Tablets

Oxydrol BD also shuts down natural testosterone production. It is regarded by the bodybuilding community as the most effective oral steroid in building strength and size. Oxydrol BD has many side effects however, which make it relatively unsafe to use when compared to other steroids. Average dose is 50-100 mg per day to 200 mg per day. Oxydrol BD is used on bulking cycle with Sustanon and deca-durabolin.

Reviews

There are no reviews yet.

Be the first to review “Max-Drol”

Your email address will not be published. Required fields are marked *